<abstract xmlns="http://www.w3.org/1999/xhtml">

<bold>Background</bold>: Head and neck carcinomas (HNC) account for a majority of ear, nose and throat tumours. They account for 6.3% of all incident malignancies and 6.2 % of all deaths from cancer in Romania in 2020, the fifth most common cancer in this Eastern Europe country. Aim of the study: The aim of our study was to investigate the association between two MMP-2 and MMP-9 promoter gene polymorphisms and head and neck cancer.
<bold>Methods</bold>. We enrolled 142 subjects, 65 cancer patients, and 77 control subjects and tested them for MMP-2 -735 C/T and MMP-9 -1562 C/T polymorphisms by PCR-RFLP.
<bold>Results</bold>. Comparison between cancer patients and controls demonstrated the presence of MMP-2 -735 C/T and MMP-9 -1562 C/T in head and neck malignant tumours, with OR = 2.206 (95% CI 1.058-4.599, P = 0.03) for MMP-2 and OR = 2.748 (95% C.I. 1.262-5.981, P=0.009) for MMP-9 gene polymorphism. This means that the presence of T allele could be a risk factor for head and neck cancer development. The analysis included a stratification of studied groups by age and gender.
<bold>Conclusions</bold>. Both genotypes were associated with a significant risk for head and neck carcinomas in case of the presence of the T allele. MMP-2 -735 C/T (rs2285053) and MMP-9 -1562 C/T (rs3918242) gene polymorphism could be an important genetic marker for head and neck cancer susceptibility. This finding could be useful for genetic screening in head and neck carcinomas.
</abstract>

Background: Head and neck carcinomas (HNC) account for a majority of ear, nose and throat tumours. They account for 6.3% of all incident malignancies and 6.2 % of all deaths from cancer in Romania in 2020, the fifth most common cancer in this Eastern Europe country. Aim of the study: The aim of our study was to investigate the association between two MMP-2 and MMP-9 promoter gene polymorphisms and head and neck cancer.
Methods. We enrolled 142 subjects, 65 cancer patients, and 77 control subjects and tested them for MMP-2 -735 C/T and MMP-9 -1562 C/T polymorphisms by PCR-RFLP.
Results. Comparison between cancer patients and controls demonstrated the presence of MMP-2 -735 C/T and MMP-9 -1562 C/T in head and neck malignant tumours, with OR = 2.206 (95% CI 1.058-4.599, P = 0.03) for MMP-2 and OR = 2.748 (95% C.I. 1.262-5.981, P=0.009) for MMP-9 gene polymorphism. This means that the presence of T allele could be a risk factor for head and neck cancer development. The analysis included a stratification of studied groups by age and gender.
Conclusions. Both genotypes were associated with a significant risk for head and neck carcinomas in case of the presence of the T allele. MMP-2 -735 C/T (rs2285053) and MMP-9 -1562 C/T (rs3918242) gene polymorphism could be an important genetic marker for head and neck cancer susceptibility. This finding could be useful for genetic screening in head and neck carcinomas.

MMP-2 and MMP-9 gene polymorphisms and risk of head and neck carcinomas

Otorhynolaryngology, “Carol Davila” University of Medicine and Pharmacy

Revista Romana de Medicina de Laborator

This work is licensed under the Creative Commons Attribution 4.0 International License.

{"article-title":"MMP-2 and MMP-9 gene polymorphisms and risk of head and neck carcinomas"}

Background: Head and neck carcinomas (HNC) account for a majority of ear, nose and throat tumours. They account for 6.3% of all incident malignancies and 6.2 %...

MMP-2 and MMP-9 gene polymorphisms and risk of head and neck carcinomas

Online veröffentlicht: 09. Mai 2022

Seitenbereich: 163 - 171

Eingereicht: 10. Juni 2021

Akzeptiert: 28. Jan. 2022

DOI: https://doi.org/10.2478/rrlm-2022-0010

Schlüsselwörter
risk, polymorphism, MMP-9, MMP-2, head and neck squamous cell carcinomas

© 2022 Sorina Schipor et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

MMP-2 and MMP-9 gene polymorphisms and risk of head and neck carcinomas

Online veröffentlicht: 09. Mai 2022

Seitenbereich: 163 - 171

Eingereicht: 10. Juni 2021

Akzeptiert: 28. Jan. 2022

DOI: https://doi.org/10.2478/rrlm-2022-0010

Schlüsselwörterrisk, polymorphism, MMP-9, MMP-2, head and neck squamous cell carcinomas

© 2022 Sorina Schipor et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Schlüsselwörter
risk, polymorphism, MMP-9, MMP-2, head and neck squamous cell carcinomas